S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.49 (+1.86%)
AAPL   111.97 (+1.72%)
MSFT   207.39 (+2.39%)
FB   254.36 (+2.50%)
GOOGL   1,459.03 (+2.02%)
AMZN   3,124.98 (+5.56%)
NVDA   504.82 (+0.82%)
TSLA   425.68 (-5.28%)
BABA   275.40 (+0.58%)
CGC   16.01 (+1.72%)
GE   6.23 (-1.89%)
MU   49.62 (+0.96%)
AMD   77.62 (-0.41%)
T   28.50 (-0.45%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.99 (+0.75%)
DIS   127.08 (+1.33%)
BAC   23.87 (-2.45%)
BA   156.89 (+0.35%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.49 (+1.86%)
AAPL   111.97 (+1.72%)
MSFT   207.39 (+2.39%)
FB   254.36 (+2.50%)
GOOGL   1,459.03 (+2.02%)
AMZN   3,124.98 (+5.56%)
NVDA   504.82 (+0.82%)
TSLA   425.68 (-5.28%)
BABA   275.40 (+0.58%)
CGC   16.01 (+1.72%)
GE   6.23 (-1.89%)
MU   49.62 (+0.96%)
AMD   77.62 (-0.41%)
T   28.50 (-0.45%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.99 (+0.75%)
DIS   127.08 (+1.33%)
BAC   23.87 (-2.45%)
BA   156.89 (+0.35%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.49 (+1.86%)
AAPL   111.97 (+1.72%)
MSFT   207.39 (+2.39%)
FB   254.36 (+2.50%)
GOOGL   1,459.03 (+2.02%)
AMZN   3,124.98 (+5.56%)
NVDA   504.82 (+0.82%)
TSLA   425.68 (-5.28%)
BABA   275.40 (+0.58%)
CGC   16.01 (+1.72%)
GE   6.23 (-1.89%)
MU   49.62 (+0.96%)
AMD   77.62 (-0.41%)
T   28.50 (-0.45%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.99 (+0.75%)
DIS   127.08 (+1.33%)
BAC   23.87 (-2.45%)
BA   156.89 (+0.35%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.49 (+1.86%)
AAPL   111.97 (+1.72%)
MSFT   207.39 (+2.39%)
FB   254.36 (+2.50%)
GOOGL   1,459.03 (+2.02%)
AMZN   3,124.98 (+5.56%)
NVDA   504.82 (+0.82%)
TSLA   425.68 (-5.28%)
BABA   275.40 (+0.58%)
CGC   16.01 (+1.72%)
GE   6.23 (-1.89%)
MU   49.62 (+0.96%)
AMD   77.62 (-0.41%)
T   28.50 (-0.45%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.52 (-1.07%)
NFLX   490.99 (+0.75%)
DIS   127.08 (+1.33%)
BAC   23.87 (-2.45%)
BA   156.89 (+0.35%)
Log in
NASDAQ:BNGO

BioNano Genomics Stock Forecast, Price & News

$0.63
0.00 (-0.41 %)
(As of 09/22/2020 03:51 PM ET)
Add
Compare
Today's Range
$0.61
Now: $0.63
$0.65
50-Day Range
$0.49
MA: $0.65
$0.86
52-Week Range
$0.25
Now: $0.63
$4.70
Volume99,222 shs
Average Volume11.57 million shs
Market Capitalization$87.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BNGO
CUSIPN/A
CIKN/A
Phone858-888-7600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.13 million
Book Value$0.11 per share

Profitability

Net Income$-29,820,000.00
Net Margins-390.52%
Return on Equity-15,217.90%

Miscellaneous

Employees77
Market Cap$87.57 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$0.63
0.00 (-0.41 %)
(As of 09/22/2020 03:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BNGO News and Ratings via Email

Sign-up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioNano Genomics (NASDAQ:BNGO) Frequently Asked Questions

How has BioNano Genomics' stock been impacted by COVID-19?

BioNano Genomics' stock was trading at $0.5770 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BNGO stock has increased by 7.2% and is now trading at $0.6187.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of BioNano Genomics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNano Genomics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioNano Genomics
.

When is BioNano Genomics' next earnings date?

BioNano Genomics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for BioNano Genomics
.

How were BioNano Genomics' earnings last quarter?

BioNano Genomics Inc (NASDAQ:BNGO) announced its quarterly earnings data on Thursday, August, 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.00. The company had revenue of $1.18 million for the quarter, compared to analysts' expectations of $0.73 million. BioNano Genomics had a negative net margin of 390.52% and a negative return on equity of 15,217.90%.
View BioNano Genomics' earnings history
.

What price target have analysts set for BNGO?

3 equities research analysts have issued 12-month target prices for BioNano Genomics' stock. Their forecasts range from $1.00 to $2.00. On average, they expect BioNano Genomics' share price to reach $1.50 in the next twelve months. This suggests a possible upside of 142.4% from the stock's current price.
View analysts' price targets for BioNano Genomics
.

Are investors shorting BioNano Genomics?

BioNano Genomics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 5,050,000 shares, an increase of 16.9% from the August 15th total of 4,320,000 shares. Based on an average daily trading volume, of 23,160,000 shares, the days-to-cover ratio is presently 0.2 days.
View BioNano Genomics' Short Interest
.

Who are some of BioNano Genomics' key competitors?

What other stocks do shareholders of BioNano Genomics own?

Who are BioNano Genomics' key executives?

BioNano Genomics' management team includes the following people:
  • Dr. Robert Erik Holmlin, Pres, CEO & Director (Age 51)
  • Mr. Michael J. Ward, Chief Financial Officer (Age 47)
  • Mr. Warren Robinson, Chief Commercial Officer (Age 50)
  • Mr. Mark Borodkin, Chief Operating Officer (Age 45)
  • Heather Adams, Sec.

When did BioNano Genomics IPO?

(BNGO) raised $16 million in an initial public offering (IPO) on the week of August 20th 2018. The company issued 2,500,000 shares at $6.00-$7.00 per share. Roth Capital Partners and Maxim Group acted as the underwriters for the IPO and LifeSci Capital was co-manager.

What is BioNano Genomics' stock symbol?

BioNano Genomics trades on the NASDAQ under the ticker symbol "BNGO."

Who are BioNano Genomics' major shareholders?

BioNano Genomics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.24%).
View institutional ownership trends for BioNano Genomics
.

Which institutional investors are buying BioNano Genomics stock?

BNGO stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for BioNano Genomics
.

How do I buy shares of BioNano Genomics?

Shares of BNGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioNano Genomics' stock price today?

One share of BNGO stock can currently be purchased for approximately $0.62.

How big of a company is BioNano Genomics?

BioNano Genomics has a market capitalization of $85.68 million and generates $10.13 million in revenue each year. The company earns $-29,820,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. BioNano Genomics employs 77 workers across the globe.

What is BioNano Genomics' official website?

The official website for BioNano Genomics is www.bionanogenomics.com.

How can I contact BioNano Genomics?

BioNano Genomics' mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The company can be reached via phone at 858-888-7600 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.